Gilead Sciences Inc (NAS:GILD)
$ 67.9 0.18 (0.27%) Market Cap: 84.59 Bil Enterprise Value: 104.85 Bil PE Ratio: 188.61 PB Ratio: 4.83 GF Score: 74/100

Gilead Sciences Inc to Acquire Immunomedics Inc Conference Call Transcript

Sep 13, 2020 / 09:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today to Douglas Maffei, Senior Director, Investor Relations. Thank you. Please go ahead.

Douglas Maffei
Gilead Sciences, Inc. - Senior Director of IR

Thank you, Dilem. We appreciate everyone joining us on short notice for today's call to discuss the exciting acquisition of Immunomedics announced earlier today. The speakers on today's call will be Daniel O'Day, Chairman and Chief Executive Officer; Merdad Parsey, Chief Medical Officer; Johanna Mercier, Chief Commercial Officer; and Andrew Dickinson, Chief Financial Officer.

Before we begin, let me remind you that we will be making forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in any forward-looking statements.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot